|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RESF1 |
Gene summary for RESF1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RESF1 | Gene ID | 55196 |
| Gene name | retroelement silencing factor 1 | |
| Gene Alias | C12orf35 | |
| Cytomap | 12p11.21 | |
| Gene Type | protein-coding | GO ID | GO:0006325 | UniProtAcc | Q9HCM1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55196 | RESF1 | AEH-subject1 | Human | Endometrium | AEH | 2.45e-51 | 7.32e-01 | -0.3059 |
| 55196 | RESF1 | AEH-subject2 | Human | Endometrium | AEH | 1.77e-23 | 5.19e-01 | -0.2525 |
| 55196 | RESF1 | AEH-subject3 | Human | Endometrium | AEH | 1.92e-21 | 4.60e-01 | -0.2576 |
| 55196 | RESF1 | AEH-subject4 | Human | Endometrium | AEH | 1.16e-26 | 6.25e-01 | -0.2657 |
| 55196 | RESF1 | AEH-subject5 | Human | Endometrium | AEH | 7.70e-42 | 7.09e-01 | -0.2953 |
| 55196 | RESF1 | EEC-subject1 | Human | Endometrium | EEC | 4.77e-29 | 6.01e-01 | -0.2682 |
| 55196 | RESF1 | EEC-subject2 | Human | Endometrium | EEC | 1.36e-43 | 7.04e-01 | -0.2607 |
| 55196 | RESF1 | EEC-subject3 | Human | Endometrium | EEC | 8.71e-07 | 3.60e-01 | -0.2525 |
| 55196 | RESF1 | EEC-subject4 | Human | Endometrium | EEC | 7.64e-34 | 6.11e-01 | -0.2571 |
| 55196 | RESF1 | EEC-subject5 | Human | Endometrium | EEC | 2.82e-42 | 7.04e-01 | -0.249 |
| 55196 | RESF1 | LZE2D | Human | Esophagus | HGIN | 1.57e-04 | 6.32e-01 | 0.0642 |
| 55196 | RESF1 | LZE4T | Human | Esophagus | ESCC | 6.29e-20 | 5.31e-01 | 0.0811 |
| 55196 | RESF1 | LZE5T | Human | Esophagus | ESCC | 1.15e-08 | 5.15e-01 | 0.0514 |
| 55196 | RESF1 | LZE7T | Human | Esophagus | ESCC | 4.27e-18 | 7.24e-01 | 0.0667 |
| 55196 | RESF1 | LZE8T | Human | Esophagus | ESCC | 1.68e-29 | 8.61e-01 | 0.067 |
| 55196 | RESF1 | LZE20T | Human | Esophagus | ESCC | 2.66e-23 | 6.73e-01 | 0.0662 |
| 55196 | RESF1 | LZE21D1 | Human | Esophagus | HGIN | 4.41e-04 | 3.94e-01 | 0.0632 |
| 55196 | RESF1 | LZE24T | Human | Esophagus | ESCC | 6.51e-29 | 5.93e-01 | 0.0596 |
| 55196 | RESF1 | LZE21T | Human | Esophagus | ESCC | 1.16e-05 | 3.22e-01 | 0.0655 |
| 55196 | RESF1 | LZE6T | Human | Esophagus | ESCC | 6.79e-20 | 6.39e-01 | 0.0845 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001603216 | Endometrium | AEH | viral process | 110/2100 | 415/18723 | 1.99e-18 | 1.09e-15 | 110 |
| GO:001905816 | Endometrium | AEH | viral life cycle | 86/2100 | 317/18723 | 2.53e-15 | 7.58e-13 | 86 |
| GO:001907916 | Endometrium | AEH | viral genome replication | 43/2100 | 131/18723 | 3.22e-11 | 4.60e-09 | 43 |
| GO:005079216 | Endometrium | AEH | regulation of viral process | 40/2100 | 164/18723 | 1.46e-06 | 4.66e-05 | 40 |
| GO:200125210 | Endometrium | AEH | positive regulation of chromosome organization | 25/2100 | 82/18723 | 1.95e-06 | 5.93e-05 | 25 |
| GO:190390016 | Endometrium | AEH | regulation of viral life cycle | 36/2100 | 148/18723 | 5.13e-06 | 1.32e-04 | 36 |
| GO:00450699 | Endometrium | AEH | regulation of viral genome replication | 23/2100 | 85/18723 | 4.25e-05 | 7.20e-04 | 23 |
| GO:00396942 | Endometrium | AEH | viral RNA genome replication | 12/2100 | 35/18723 | 2.69e-04 | 3.12e-03 | 12 |
| GO:00330446 | Endometrium | AEH | regulation of chromosome organization | 36/2100 | 187/18723 | 8.27e-04 | 7.73e-03 | 36 |
| GO:00485257 | Endometrium | AEH | negative regulation of viral process | 21/2100 | 92/18723 | 1.10e-03 | 9.61e-03 | 21 |
| GO:00450715 | Endometrium | AEH | negative regulation of viral genome replication | 14/2100 | 56/18723 | 2.92e-03 | 2.08e-02 | 14 |
| GO:00063258 | Endometrium | AEH | chromatin organization | 64/2100 | 409/18723 | 3.69e-03 | 2.52e-02 | 64 |
| GO:0031453 | Endometrium | AEH | positive regulation of heterochromatin assembly | 5/2100 | 12/18723 | 7.10e-03 | 4.09e-02 | 5 |
| GO:0120263 | Endometrium | AEH | positive regulation of heterochromatin organization | 5/2100 | 12/18723 | 7.10e-03 | 4.09e-02 | 5 |
| GO:001603217 | Endometrium | EEC | viral process | 112/2168 | 415/18723 | 2.48e-18 | 1.35e-15 | 112 |
| GO:001905817 | Endometrium | EEC | viral life cycle | 86/2168 | 317/18723 | 1.63e-14 | 4.65e-12 | 86 |
| GO:001907917 | Endometrium | EEC | viral genome replication | 42/2168 | 131/18723 | 3.43e-10 | 3.61e-08 | 42 |
| GO:200125213 | Endometrium | EEC | positive regulation of chromosome organization | 26/2168 | 82/18723 | 9.70e-07 | 3.31e-05 | 26 |
| GO:005079217 | Endometrium | EEC | regulation of viral process | 40/2168 | 164/18723 | 3.24e-06 | 8.85e-05 | 40 |
| GO:190390017 | Endometrium | EEC | regulation of viral life cycle | 36/2168 | 148/18723 | 1.05e-05 | 2.25e-04 | 36 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |